Anti-NRX2B/ NRX2A/ NRXN2 monoclonal antibody

Anti-NRX2B/ NRX2A/ NRXN2 antibody for FACS & in-vivo assay

Target products collectionGo to NRXN2/NRXN2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0909-Ab-1/ GM-Tg-hg-MP0909-Ab-2Anti-Human NRXN2 monoclonal antibodyHuman
GM-Tg-rg-MP0909-Ab-1/ GM-Tg-rg-MP0909-Ab-2Anti-Rat NRXN2 monoclonal antibodyRat
GM-Tg-mg-MP0909-Ab-1/ GM-Tg-mg-MP0909-Ab-2Anti-Mouse NRXN2 monoclonal antibodyMouse
GM-Tg-cynog-MP0909-Ab-1/ GM-Tg-cynog-MP0909-Ab-2Anti-Cynomolgus/ Rhesus macaque NRXN2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0909-Ab-1/ GM-Tg-felg-MP0909-Ab-2Anti-Feline NRXN2 monoclonal antibodyFeline
GM-Tg-cang-MP0909-Ab-1/ GM-Tg-cang-MP0909-Ab-2Anti-Canine NRXN2 monoclonal antibodyCanine
GM-Tg-bovg-MP0909-Ab-1/ GM-Tg-bovg-MP0909-Ab-2Anti-Bovine NRXN2 monoclonal antibodyBovine
GM-Tg-equg-MP0909-Ab-1/ GM-Tg-equg-MP0909-Ab-2Anti-Equine NRXN2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0909-Ab-1/ GM-Tg-hg-MP0909-Ab-2; GM-Tg-rg-MP0909-Ab-1/ GM-Tg-rg-MP0909-Ab-2;
GM-Tg-mg-MP0909-Ab-1/ GM-Tg-mg-MP0909-Ab-2; GM-Tg-cynog-MP0909-Ab-1/ GM-Tg-cynog-MP0909-Ab-2;
GM-Tg-felg-MP0909-Ab-1/ GM-Tg-felg-MP0909-Ab-2; GM-Tg-cang-MP0909-Ab-1/ GM-Tg-cang-MP0909-Ab-2;
GM-Tg-bovg-MP0909-Ab-1/ GM-Tg-bovg-MP0909-Ab-2; GM-Tg-equg-MP0909-Ab-1/ GM-Tg-equg-MP0909-Ab-2
Products NameAnti-NRXN2 monoclonal antibody
Formatmab
Target NameNRXN2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NRXN2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NRX2B/ NRX2A/ NRXN2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0909
    Target NameNRXN2
    Gene ID9379,18190,116595,574175,101094207,537808,100055880
    Gene Symbol and Synonyms6430591O13Rik,mKIAA0921,NRXN2
    Uniprot AccessionP58401, Q9P2S2,Q63374,Q63376
    Uniprot Entry NameNRX2A_HUMAN,NRX2A_RAT,NRX2B_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000110076
    Target ClassificationN/A

    The target: NRXN2, gene name: NRXN2, also named as . This gene encodes a member of the neurexin gene family. The products of these genes function as cell adhesion molecules and receptors in the vertebrate nervous system. These genes utilize two promoters. The majority of transcripts are produced from the upstream promoter and encode alpha-neurexin isoforms while a smaller number of transcripts are produced from the downstream promoter and encode beta-neuresin isoforms. The alpha-neurexins contain epidermal growth factor-like (EGF-like) sequences and laminin G domains, and have been shown to interact with neurexophilins. The beta-neurexins lack EGF-like sequences and contain fewer laminin G domains than alpha-neurexins. Alternative splicing and the use of alternative promoters may generate thousands of transcript variants (PMID: 12036300, PMID: 11944992).[provided by RefSeq, Jun 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.